Omberacetam (Noopept)
Synthetic Dipeptide | Cognitive Enhancement Nootropic
On this page
What is Omberacetam (Noopept)?
Omberacetam (also called Noopept) is a small synthetic dipeptide-like compound studied in the nootropic research literature for its effects on memory and learning pathways, at doses reported to be far smaller than older compounds in its class. Once absorbed, it's converted into an active byproduct that researchers study for its influence on glutamate signaling and BDNF levels. It's sold here strictly as a research chemical for laboratory study, not for use in people or animals.
Key terms:
Omberacetam (Noopept) is a synthetic dipeptide.
Omberacetam (also called Noopept or GVS-111) is a lab-made two-amino-acid compound, N-phenylacetyl-L-prolylglycine ethyl ester. It was developed in Russia in 1996 and studied for strong effects on thinking and for neuroprotection (shielding nerve cells from damage). Its structure differs from the racetams, but it is grouped with them as a nootropic. It is a prodrug: the body converts it into an active byproduct called cycloprolylglycine (CPG). Research suggests it may support memory, learning, and neuroplasticity by increasing BDNF and NGF (nerve-growth signals) and by adjusting glutamate signaling — at doses 1,000 times lower than piracetam.
Key research areas
- Primary administration route with rapid oral bioavailability
- Convenient dosing with peak absorption within 7 minutes
- Well-studied in clinical trials
- Enhances memory consolidation and retrieval
- Supports neuroplasticity through BDNF/NGF upregulation
- Effective at doses 1000x lower than piracetam
Researched dosing
This table shows how researchers have structured study dosing schedules for Omberacetam — published research methodology and dose ranges, not personal usage instructions.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Cognitive studies (lower dose) | 10mg | 1-2 times daily | Oral (sublingual or swallowed) |
| Standard cognitive studies | 10-20mg | 2-3 times daily | Oral, taken with or without food |
| Higher-dose cognitive studies | 20-30mg | 2-3 times daily | Oral, cycled 4-8 weeks |
| Cognitive-recovery studies | 20mg | Twice daily | Oral (as studied in clinical trials) |
| Lower-dose tolerability studies | 5-10mg | Once daily | Sublingual for enhanced absorption |
Commonly cycled 8 weeks on, 2+ weeks off.
How it works
At the cell level, Omberacetam research looks at how its active byproduct (cycloprolylglycine) interacts with glutamate receptors and cholinergic signaling — the proposed basis for the memory- and learning-related effects reported in the literature.
Rapidly absorbed orally and converted to active metabolite cycloprolylglycine (CPG) which modulates AMPA/NMDA glutamate receptors and enhances cholinergic neurotransmission
Research applications
This section lists the body systems and research areas scientists have studied for Omberacetam — largely memory, learning, and neuroprotection research — a summary of what's been investigated in the literature, not medical claims about people.
Cognitive
Improved memory consolidation and retrieval through enhanced synaptic plasticity and neurotrophic factor expression. Faster acquisition of new information via AMPA receptor modulation and enhanced long-term potentiation. Sustained attention improvements through acetylcholine sensitization and glutamatergic enhancement.
Neuroprotective
Demonstrates significant neuroprotective effects against Alzheimer's disease-related pathology, attenuating apoptosis and reducing tau hyperphosphorylation in human neuronal cells exposed to amyloid-beta toxicity.
Neuroplasticity
Elevates BDNF and NGF mRNA levels in the hippocampus, supporting synaptic plasticity and long-term neuroplasticity benefits.
Dosage reference
- Doses used in research
- 10–20 mg per dose
- Frequency in studies
- 1-3 times daily, morning and early afternoon preferred
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Onset 20-60 minutes, peak 2 hours, duration 3-5 hours
- Storage
- Room temperature, protect from moisture and light
- Cycle length
- 4-8 weeks continuous use recommended
- Break between cycles
- 2-4 weeks break between cycles to prevent tolerance
Interactions
This list shows which other nootropic-research compounds scientists study alongside Omberacetam, and notes that a dietary choline source is often included in study designs to offset a commonly reported research finding (mild headache).
Reconstitution & storage
Omberacetam is typically studied as tablets, capsules, or a measured powder rather than an injectable, so this section covers precise measurement and choline-pairing notes instead of a mixing procedure.
- Omberacetam is typically supplied as tablets (10mg), capsules, or powder form
- For powder: Use precision scale capable of measuring milligrams accurately
- Consider pairing with a choline source (Alpha-GPC 300mg or CDP-Choline 250mg) to prevent headaches
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: Room temperature, use within Not specified
Reconstituted: 2-6°C, use within Not specified
Quality indicators
These are the visual and lab-report checks researchers use to confirm an Omberacetam sample is pure and correctly identified before it goes into a study.
White crystalline powder - Omberacetam should be white to off-white crystalline powder without discoloration
Third-party testing - Certificate of analysis showing purity ≥98% with HPLC verification
Proper packaging - Sealed containers protected from moisture with desiccant packets
Accurate dosing - Tablets/capsules should contain stated amount (typically 10mg per unit)
Headache potential - May cause headaches if taken without adequate choline - supplement accordingly
Discoloration or clumping - Yellow discoloration or excessive clumping may indicate degradation or contamination
What to expect
This timeline summarizes what research literature reports at each stage of a study — research context for comparing studies, not a personal-results promise.
Subtle cognitive clarity and mild focus enhancement; possible initial headache if not using choline
Noticeable improvement in memory recall and verbal fluency; adjust dosing as needed
Enhanced learning capacity and sustained attention; mood stabilization effects may emerge
Peak cognitive benefits with improved stress resilience and mental stamina
Sustained effects; consider cycle break to maintain sensitivity
Safety notes
This section covers handling cautions and regulatory notes for Omberacetam in a laboratory setting — research-use-only scope and interaction flags drawn from the literature, not medical safety advice for people.
- Start with 10mg once daily to assess individual response before increasing dose
- Always pair with a choline source (Alpha-GPC or CDP-Choline) to prevent headaches
- Avoid evening dosing as cognitive stimulation may interfere with sleep
- Do not combine with other strong cholinergic or glutamatergic compounds without caution
- Not recommended for pregnant or breastfeeding women due to lack of safety data
- Individuals with liver conditions should consult healthcare provider before use
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
Omberacetam demonstrated significant neuroprotective effects against Alzheimer's disease-related pathology, attenuating apoptosis and reducing tau hyperphosphorylation in human neuronal cells exposed to amyloid-beta toxicity.
Acute administration elevated BDNF mRNA levels by up to 1.4-fold and NGF mRNA by 1.3-fold in hippocampus within 3 hours post-injection, demonstrating rapid neurotrophic activity supporting neuroplasticity.
Patients with cognitive impairment from vascular cerebral damage or post-traumatic injury showed universal improvement on measured parameters. MMSE scores increased from 26 to 29 in the Omberacetam group with 1.8-fold fewer side effects compared to piracetam.